ENTPD1 and neoplasm: Interestingly, intraperitoneal treatment of tumor-bearing mice with antisense oligonucleotides targeting CD39 augmented CD8+ T cell proliferation, reduced CD39 expression by tumor and Tregs, and enhanced anti–PD-1 treatment (145).